Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan-Reference-Cited by-同舟云学术

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

Published:2022-11-07 Issue:12 Volume:24 Page:2307-2319
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Yang Mingming¹²,Butt Jawad H.¹³,Kondo Toru¹⁴,Jering Karola S.⁵,Docherty Kieran F.¹,Jhund Pardeep S.¹,de Boer Rudolf A.⁶,Claggett Brian L.⁵,Desai Akshay S.⁵,Hernandez Adrian F.⁷,Inzucchi Silvio E.⁸,Kosiborod Mikhail N.⁹,Lam Carolyn S.P.¹⁰,Langkilde Anna Maria¹¹,Martinez Felipe A.¹²,Petersson Magnus¹¹,Shah Sanjiv J.¹³,Vaduganathan Muthiah⁵,Wilderäng Ulrica¹¹,Solomon Scott D.⁵,McMurray John J.V.¹

Affiliation:

1. British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK

2. Department of Cardiology, Zhongda Hospital, School of Medicine Southeast University Nanjing China

3. Department of Cardiology Copenhagen University Copenhagen Denmark

4. Department of Cardiology Nagoya University Graduate School of Medicine Nagoya Japan

5. Cardiovascular Division Brigham and Women's Hospital Boston MA USA

6. Erasmus Medical Center Rotterdam The Netherlands

7. Duke University Medical Center Durham NC USA

8. Yale School of Medicine New Haven CT USA

9. Saint Luke's Mid America Heart Institute University of Missouri Kansas City MS USA

10. National Heart Center Singapore and Duke–National University of Singapore Singapore

11. Late‐Stage Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals Research and Development Gothenburg Sweden

12. National University of Cordoba Cordoba Colombia

13. Northwestern University Feinberg School of Medicine Chicago IL USA

Funder

British Heart Foundation

China Scholarship Council

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2722

Reference24 articles.

1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich PA;Circulation,2022

3. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

4. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

5. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of ARNI (Sacubitril/Valsartan) and SGLT2 Inhibitors (Dapagliflozin) either alone or in Combination on Heart Failure: An Exploration of Novelty;Journal of Young Pharmacists;2024-08-23

2. Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment;European Journal of Heart Failure;2024-08-21

3. 2024 update in heart failure;ESC Heart Failure;2024-05-28

4. Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India;Cardiology and Therapy;2024-04-30

5. Obesity: the perfect storm for heart failure;ESC Heart Failure;2024-03-15